Status of Total Antioxidant Capacity and Malondialdehyde Level in Methamphetamine Addicts: A Cross Sectional Study

S Shadnia, N Gorgzadeh, K Soltaninejad, M Abdollahi, SA Motevalian

1

Abstract

Background: Methamphetamine (MA) is an illegal amphetamine-like which stimulate the central nervous system. In recent years, MA has been widely abused worldwide. Previous studies have suggested that oxidative stress (OS) plays an important role in MA-induced toxicity. From this view, antioxidant therapy could be considered as a potential drug therapy in MA abusers. Therefore, the objective of this study was to evaluate OS status in MA abusers.

Methods: This was a cross-sectional study conducted on 21 MA abusers who referred to Iranian National Center for Addiction Studies and Congress 60 Humane Revivification Society, and 15 healthy males as a control group. The demographic data and peripheral blood sampling was obtained from both groups. The serum malondialdehyde (MDA) level as a marker of plasma lipid peroxidation and total antioxidant capacity (TAC) of plasma were analyzed.

Results: Significant decrease in plasma TAC in case group was observed (101.85±12.5 vs. 130.7±16.12 mmol/L). No significant increase in MDA serum level was detected in case group in comparison with control (27.35±2.6 vs. 26.67±2.22 µmol/L, respectively). Neither the serum MDA levels nor the plasma TAC were significantly correlated with the duration and amount of MA abuse.

Conclusion: It seems that, MA abuse is associated with prooxidant-antioxidant imbalance, which suggests evaluation the role of antioxidants administration for the prevention and treatment of MA-induced toxicity.

Keywords

Abuse, Antioxidant, Malondialdehyde, Methamphetamine, Oxidative stress

Full Text:

PDF

References

Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007;76(8):1169-74.

World Health Organization (WHO). Amphetamine-type stimulants. Available at: https://www.who.int/substance_abuse/facts/ATS/en/ Accessed on 12 August 2016.

Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008;27:253-62.

Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract. 2011:24:541-50.

Rawson RA, Gonzales R, Marinelli-Casey P, Ang A. Methamphetamine dependence: a closer look at treatment response and clinical characteristics associated with route of administration in outpatient treatment. Am J Addict. 2007;16:291-99.

Rawson R, Marinelli-Casey P, Anglin MD, Dickow A, et al. Methamphetamine treatment project corporate authors. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99:708-17.

Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev. 2001;36:1-22.

Simoes PF, Silva AP, Pereira FC, Margues E, et al. Methamphetamine changes NMDA and AMPA glutamate receptor subunit levels in the rat striatum and frontal cortex. Ann NY Acad Sci. 2008;39:232-41.

Lavoie MJ, Hastings TG. Dopamine quinine formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci. 1999;19(4):1484-91.

Kita T, Takahashi M, Kubo K, Wagner GC, et al. Hydroxyl radical formation following methamphetamine administration to rats. Pharmacol Toxicol. 1999; 85:133-37.

Yamamoto BK, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther. 1998;287:107-14.

Lau JVV, Senok S, Stadlin A. Methamphetamine-induced oxidative stress in cultured mouse astrocytes. Ann NY Acad Sci. 2000;914:146-56.

Zhang X, Benerjee A, Banks WA, Ercal N. N-acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells. Brain Res. 2009; 1275:87-95.

Ramirez SH, Potula R, Fan S, Eidem T, et al. Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab. 2009;29(12):1933-45.

Pubill D, Chipana C, Camins A, Pallas M, et al. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol. 2005;204(1):57-68.

Walker J, Winhusen T, Storkson JM, Lewis D, et al. Total antioxidant capacity is significantly lower in cocaine-dependant and methamphetamine-dependent patients relative to normal controls: results from a preliminary study. Hum Psychopharmacol. 2014; 29(6):537-43.

Suriyaprom K, Tanateerabunjong R, Tungtrongcorhitr A, Tungtrongchitr R. Alterations in malondialdehyde levels and laboratory parameters among methamphetamine abusers. J Med Assoc Thai. 2011;94(12):1533-39.

Huang MC, Lin SK, Chen CH, Pan CH, et al. Oxidative stress status in recently abstinent methamphetamine abusers. Psychiatry Clin Neurosci. 2013;67(2):92-100.

Fitzmaurice PS, Tong J, Yazdanpanah M, Liu PP, et al. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J Pharmacol Exp Ther. 2006;319(2):703-9.

Betteridge DJ. What is oxidative stress? Metabolism. 2000;49:3-8.

Therond P. Oxidative stress and damages to biomolecules (lipids, proteins, DNA). Ann Pharm Fr. 2006;64(6):383-89.

Valko M, Leibfritz D, Moncol J, Cronin MT, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int Biochem Cell Biol. 2007;39(1):44-84.

Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316-28.

Kusano C, Ferrari B. Total antioxidant capacity: a biomarker in biomedical and nutritional studies. J Cell Mol Biol. 2008;7:1-15.

Zhang JX, Zhang DA M, Han XG. Identification of impurities and statistical classification of methamphetamine hydrochloride drugs seized in china. Forensic Sci Int. 2008;182(1-3):13-9.

Khajeamiri AR, Faizi M, Sohani F, Baheri T, et al. Determination of impurities in illicit methamphetamine samples seized in Iran. Forensic Sci Int. 2012;217(1-3):204-6.

Satih K. Serum lipid peroxide in cerebrovascular disorders determined by a new calorimetric method. Clin Chim Acta. 1978;90:37-43.

Benzie IE, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239:70-6.

Degenhardt L, Mathers B, Guarinieri M, Panda S, et al. Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy. 2010;21(5):347-58.

United Nations Office on Drugs and Crime (UNODC). World Drug Report 2012. Available at: https://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf Accessed on 19 September 2016.

Seiden LS, Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav. 1984;21:29-31.

Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylendioxy-methamphetamine. Brain Res. 1992;581:237-43.

Burrows KB, Gudelsky G, Yamamato BK. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3, 4-methylenedioxy-methamphetamine administration. Eur J Pharmacol. 2000;398:11-18.

Giammarioli S, Filesi C, Sanzini E. Oxidative stress markers: specificity and measurement techniques. Ann Ist Super Sanita. 1999;35(4):563-76.

Werb D, Kerr T, Zhang R, Montaner J, et al. Methamphetamine use and malnutrition among street-involved youth. Harm Reduct. 2010;7:5.